Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PTPN22 IN T1D

Financiado

Cerrado

Effect of PTPN22 on Treg to Teff equilibrium in human and murine autoimmune diab...

Effect of PTPN22 on Treg to Teff equilibrium in human and murine autoimmune diabetes "Type 1 diabetes (T1D) is a chronic inflammatory disease, where predisposing genetic factors along with environmental influences result in loss of immunological tolerance and destruction of insulin-producing beta cells. Genetic st... ver más

31/03/2015

OSR

100K€

Presupuesto del proyecto: 100K€

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-03-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

OSR

0.00€ | Lider

HSR

N.D. | Participante

Proyectos interesantes

SAF2012-35344

Medical Technol...

Immunology

291K€ Cerrado

SAF2015-66399-R

Medical Technol...

Immunology

303K€ Cerrado

MIELT1D

Medical Technol...

Immunology

119K€ Cerrado

RTI2018-097414-B-I00

Medical Technol...

Immunology

182K€ Cerrado

RYC-2010-06119

Medical Technol...

Genetics

192K€ Cerrado

DIABICLiPs

Medical Technol...

Immunology

231K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 100K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Type 1 diabetes (T1D) is a chronic inflammatory disease, where predisposing genetic factors along with environmental influences result in loss of immunological tolerance and destruction of insulin-producing beta cells. Genetic studies have identified three main T1D susceptibility loci, the human leukocyte antigens (HLA), insulin and most recently PTPN22, which encodes for Lyp/Pep, a lymphoid tyrosine phosphatase. A single nucleotide polymorphism (SNP) in PTPN22 at codon 620 leads to one amino-acid substitution, Arg to Trp (R620W), associated with an increase in T1D risk. A perturbation in the effector (Teff) to regulatory T cell (Treg) equilibrium seems to be implicated in T1D and most cases of autoimmunity. Functional analysis in individuals carrying the R620W polymorphism indicate a ""gain of function mutant"" resulting in reduced TCR signaling. However, it is not currently known how PTPN22 is involved in mediating T1D susceptibility: effects on Treg and/or Teff thymic selection and peripheral homeostasis may be responsible. Understanding the mechanisms involved could be a key to our understanding of T1D pathogenesis. In addition, strategies that directly target Teff or Treg by inhibiting signaling from PTPN22 could be successful in halting T1D progression. The goal of this project is to analyze the role of PTPN22 on Treg and Teff equilibrium in (pre)diabetic human individuals and selected mouse models of T1D. The specific aims of this Marie-Curie RIG are: 1. Define the role of PTPN22 (R620W allele) on Treg and Teff cells in healthy versus (pre)diabetic individuals, and 2. Determine the role of PTPN22 signaling on Teff and/or Treg in two well-characterized murine models of T1D, (virally-induced [RIP-LCMV] and spontaneous [NOD]. Objectives to be achieved: 1. Functional characterization of PTPN22 mutation on Treg and Teff cells in (pre)diabetic human individuals. 2. Dissection of PTPN22 signaling in selected murine models of T1D crossed to Lyp/Pep deficient mice."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores